Patent · US Expired

Use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine and its physiologically acceptable salts

US7371756B2 · kind B2 · utility

0Cited by

4References

16Claims

0Family size

Assignee

Merck Patent GmbH · DE

Inventors

Gerd Bartoszyk · Weiterstadt, DE
Christoph Seyfried · Seeheim-Jugenheim, DE
Christoph Von Amsterdam · Darmstadt, DE
Henning Boettcher · Darmstadt, DE
Ewen Sedman · Alresford, GB

Key dates

Filing date	Nov 23, 2004
Grant date	May 13, 2008
Priority date	—
Expiry date	Nov 23, 2025

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P31/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the treatment of sub-type anxiety disorders chosen from the sub-types: panic disorder with or without agoraphobia, agoraphobia, obsessive-compulsive spectrum disorders, social phobia, posttraumatic stress disorder, acute stress indication or generalized anxiety disorder, bipolar disorders, mania, dementia, substance-related disorders, sexual dysfunctions, eating disorders, obesity, anorexia, and fibromyalgia. A preferred salt is 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.